New hope for liver cancer: can immunotherapy boost standard treatment?
NCT ID NCT04712643
Summary
This study is testing whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer treatment called TACE works better than TACE alone. It involves 342 people with untreated liver cancer who are at high risk of their cancer worsening after TACE. The main goals are to see if the combination helps people live longer and keeps the cancer from progressing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Aichi, 464-8681, Japan
-
Anhui Provincial Hospital
Anhui, 230001, China
-
Beijing Tsinghua Changgung Hospital
Beijing, 102218, China
-
Beijing You An Hospital
Beijing, 100069, China
-
Chiba University Hospital
Chiba, 260-8677, Japan
-
Fudan University Shanghai Cancer Center
Shanghai, 200120, China
-
Fujian Cancer Hospital
Fuzhou, 350014, China
-
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, 530021, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Henan Cancer Hospital
Zhengzhou, 450008, China
-
Hiroshima University Hospital
Hiroshima, 734-8551, Japan
-
Hunan Cancer Hospital
Changsha, 410013, China
-
Jiangsu Cancer Hospital
Nanjing, 210009, China
-
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, 210029, China
-
Kanagawa Cancer Center
Kanagawa, 241-8515, Japan
-
Kindai University Hospital
Osaka, 589-8511, Japan
-
Kitasato University Hospital
Kanagawa, 252-0375, Japan
-
Kurume University Hospital
Fukuoka, 830-0011, Japan
-
Mengchao Hepatobiliary Hospital Of Fujian Medical University
Fuzhou, 350025, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, 510515, China
-
Peking University First Hospital
Beijing, 100034, China
-
Peking University People's Hospital
Beijing, 100044, China
-
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200127, China
-
Shengjing Hospital of China Medical University
Shenyang, 110004, China
-
Southwest Hospital , Third Military Medical University
Chongqing, 400038, China
-
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
-
The 900th Hospital of PLA joint service support force
Fuzhou, 110016, China
-
The First Affiliate Hospital of Guangxi Medical University
Nanning, 530021, China
-
The First Affiliated Hospital Of Fujian Medical University
Fuzhou, 350005, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital, Chongqing Medical University
Chongqing, 400016, China
-
The University of Osaka Hospital
Osaka, 565-0871, Japan
-
Tianjin Cancer Hospital
Tianjin, 300060, China
-
Toranomon Hospital
Tokyo, 105-8470, Japan
-
West China Hospital, Sichuan University
Chengdu, China
-
Xi'an Inernational Medical Center Hospital
Xi'an, China
-
Yokohama City University Medical Center
Kanagawa, 232-0024, Japan
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital Fudan Unvierstiy
Shanghai, China
-
Zhuhai People's Hospital
Zhuhai, 519099, China
Conditions
Explore the condition pages connected to this study.